Drug Prices and Incentives to Innovation by the Pharmaceutical Industry

2014 ◽  
pp. 389-401
Author(s):  
Rosella Levaggi ◽  
Paolo Pertile
Keyword(s):  
Pharmaceutical Industry ◽  
Drug Prices

Introduction

2021 ◽  
pp. 3-13
Author(s):  
Neumann Peter J. ◽  
Cohen Joshua T. ◽  
Ollendorf Daniel A
Keyword(s):  
Pharmaceutical Industry ◽  
Prescription Drug ◽  
Prescription Drugs ◽  
Health Expenditures ◽  
Drug Spending ◽  
Drug Pricing ◽  
Pricing Policies ◽  
Drug Prices ◽  
Financial Difficulties ◽  
Prescription Drug Spending

The pharmaceutical industry has produced wondrous scientific advances, but the progress has come at a cost. US prescription drug spending has increased faster in most recent years than other categories of health and now comprises roughly one-sixth of total health expenditures. Rising costs strain already stretched public budgets. Increasing patient out-of-pocket spending for deductibles and coinsurance has created financial difficulties for many individuals and their families, particularly among the sickest patients. The dueling trends of scientific breakthroughs and ever-rising spending present enduring challenges. On its own, rising spending would not be so concerning, but evidence suggests that drug prices often do not reflect the benefits they provide. Thus, there is an imperative to measure the value of prescription drugs and incorporate such measures into drug pricing policies.

scholarly journals Credence goods and market power: an econometric study on the Brazilian pharmaceutical industry

2003 ◽  
Vol 33 (4) ◽  
pp. 601-638
Author(s):  
Eduardo P. S. Fiuza ◽  
Marcos de B. Lisboa
Keyword(s):  
Pharmaceutical Industry ◽  
Credence Goods ◽  
Market Segment ◽  
Market Failures ◽  
Micro Data ◽  
Economic Literature ◽  
Relative Prices ◽  
Drug Prices ◽  
Branded Drugs ◽  
Econometric Study

Bearing in mind the market failures pointed out by the economic literature and following the international empirical evidence, and based on original micro data of the Brazilian pharmaceutical industry in the late 1990s, this article attempts to relate empirically drug prices in Brazil to some explaining variables. We find that, similarly to previous U.S. estimations, leading branded drugs accommodated share growth of the followers, turning towards a more inelastic market segment and raising their prices. On followers, in turn, a fall of the concentration index in a market had ambiguous effects: if due to reduced leader power, followers raised their relative prices; if due to a tougher competition within the fringe, their relative prices tended to go down.

Drug prices—The government and the pharmaceutical industry

1986 ◽  
Vol 25 (6) ◽  
pp. 671-673
Author(s):  
T. Cantopher ◽  
J.Guy Edwards ◽  
S. Olivieri
Keyword(s):  
Pharmaceutical Industry ◽  
Drug Prices ◽  
The Government

Developing a Legislative Pathway for Biosimilars in the United States

2009 ◽  
Vol 6 (4) ◽  
pp. 295-302
Author(s):  
Henry A. Waxman
Keyword(s):  
United States ◽  
Pharmaceutical Industry ◽  
The United States ◽  
High Price ◽  
Approval Process ◽  
Generic Competition ◽  
Drug Prices ◽  
Life Saving ◽  
Lower Drug ◽  
The Eu

Biologies are one of the fastest growing, most important, and most expensive segments of the pharmaceutical industry. The high price of biologies in the United States is making these life-saving drugs unaffordable for many Americans and creating unsustainable burdens on purchasers. While the EU has created an abbreviated approval process for biosimilars, there is no explicit legislative pathway in the United States that would enable generic competition for biologics. The Promoting Innovation and Access to Life-Saving Medicine Act would provide such a generic pathway for biologics, using competition to lower drug prices. The bill provides an appropriate balance between access to affordable medicine and retaining incentives for innovation.

Drug Prices and Research and Development Investment Behavior in the Pharmaceutical Industry

2005 ◽  
Vol 48 (1) ◽  
pp. 195-214 ◽  
Author(s):  
Carmelo Giaccotto ◽  
Rexford E. Santerre ◽  
John A. Vernon
Keyword(s):  
Pharmaceutical Industry ◽  
Research And Development ◽  
Investment Behavior ◽  
Drug Prices

Patient centricity: lip service or genuine commitment? A qualitative examination of the pharmaceutical industry

2020 ◽  
Vol ahead-of-print (ahead-of-print) ◽  
Author(s):  
Lea Prevel Katsanis ◽  
Dennis Pitta ◽  
Anne Morinville
Keyword(s):  
Pharmaceutical Industry ◽  
Clinical Outcomes ◽  
Future Research ◽  
Content Type ◽  
Pharmaceutical Firms ◽  
Drug Prices ◽  
Adoption And Implementation ◽  
Lowering Drug ◽  
Practical Implications ◽  
Patient Centric

Purpose The purpose of this study is two-fold: first, to identify the degree of adoption of patient centricity in the pharmaceutical industry and second, to understand how the industry operationalizes this strategy. It is an important shift in the industry because of its central focus on the patient. Design/methodology/approach A content analysis was used based on publicly available documentation that includes industry publications, company and brand websites and clinical trial publications to identify the frequency of words used to describe patient centricity. Findings The key finding of this study is that the leading pharmaceutical firms overwhelmingly use patient support/access programs as the primary method of implementing patient centric strategies. Research limitations/implications Future research is needed to identify what impact these strategies have on patients; and whether or not these strategies have an impact on lowering drug prices and improved clinical outcomes for patients. Practical implications Future research is needed to identify what impact these strategies have on patients; and whether or not these strategies have an impact on lowering drug prices and improved clinical outcomes for patients. Limitations include the reliance on publicly available documentation. Social implications Pharmaceutical firms need to be aware that their publically available profile suggests a one-dimensional approach to patient centricity and this may influence the way patients, physicians and policymakers view their attitudes toward patients. This study is the first to systematically examine the activities of leading pharmaceutical firms with respect to the adoption and implementation of patient-centric strategies in a comprehensive fashion. Originality/value This study is the first to systematically examine the activities of leading pharmaceutical firms with respect to the adoption and implementation of patient-centric strategies in a comprehensive fashion.

scholarly journals Assessment of the new Reimbursement Act functioning between January-November 2012 and its impact on pharmacies and pharmaceutical industry and oncological treatment

2016 ◽  
Vol 126 (1) ◽  
pp. 19-23
Author(s):  
Małgorzata Winiarska ◽  
Dariusz Matosiuk
Keyword(s):  
Content Analysis ◽  
Pharmaceutical Industry ◽  
Healthcare System ◽  
Numerical Data ◽  
Medicinal Products ◽  
Limit Groups ◽  
Oncological Treatment ◽  
Drug Prices ◽  
Research Material ◽  
The Way

Abstract Introduction. The new Reimbursement Act introduced on 01.01.2012 aimed at improving the way the Polish healthcare system operates, as well as reducing and unifying the prices of medicinal products. The Act provides that the prices for reimbursed drugs are lowered and unified. Increase the transparency, increase the number of innovative reimbursed drugs and lowering the level of co-payments. Aim. The authors analyze the influence of the new Reimbursement Act (introduced on 01.01.2012) over the way the Polish healthcare system works. Material and methods. The contents of the Reimbursement Act (introduced 01.01.2012) were used as research material. A content analysis of the new Act (conducted between 2013 and 2014) and its impact over the pharmaceutical industry, drug wholesale and drugstores was analyzed. Results. Some numerical data concerning retail margins, co-payments by patients, limit groups, reimbursed drug prices were showed in the study. Conclusions. Unfortunately, the Act itself has many shortcomings, inconsistencies or vague entries that require urgent amendment. Hence, it had a totally different impact.

The Business of Medicine

2017 ◽  
Author(s):  
Jessica Flanigan
Keyword(s):  
Intellectual Property ◽  
Pharmaceutical Industry ◽  
High Drug ◽  
Drug Prices ◽  
Pharmaceutical Manufacturers ◽  
Alternative Systems ◽  
Government Interference ◽  
Special Duties

Policies that prohibit manufacturers from charging high prices for drugs potentially hinder patients’ access to drugs. Popular concerns about high drug prices cannot generally justify policies that interfere with voluntary exchanges between patients and pharmaceutical manufacturers because the pharmaceutical industry is normatively different from other industries. And even if drug manufacturers did have special duties to promote patients’ health, such duties could not justify limits on drug prices. Intellectual property protections also consist in government interference with voluntary transactions between patients and manufacturers. Whether this form of interference is justified will depend on whether intellectual property laws benefit patients more than alternative systems or whether patents protect producers’ rights.

Corporatism and Big Pharma

2016 ◽  
Vol 18 (1) ◽  
pp. 36-47
Author(s):  
David Stoesz ◽  
Myra Robinson ◽  
Yomaira Carrero-Iglesia ◽  
Desiree Curry ◽  
Tylencia Selph ◽  
...  
Keyword(s):  
Public Policy ◽  
Pharmaceutical Industry ◽  
Federal Government ◽  
Socially Responsible ◽  
Charitable Contributions ◽  
Drug Prices ◽  
Drug Companies ◽  
Patient Assistance ◽  
Regulatory Reforms

The pharmaceutical industry has leveraged public policy to its benefit, prohibiting the federal government from discounts on drug prices through bulk purchases while using the tax code to develop Patient Assistance Foundations to claim charitable contributions as well as justifying moving income overseas to reduce tax liability. Consumers and taxpayers are left covering the costs of Big Pharma’s corporatism. Regulatory reforms are proposed to make drug companies more socially responsible.

Sign in / Sign up

Export Citation Format

Share Document